A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel
A phase 2 trial of Tiragolumab, Pembrolizumab, Axitinib in renal cell carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma is a phase 2 interventional study registered as NCT05805501 by Hoffmann-La Roche, with 199 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2026-10-08. Interventions recorded: Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Tiragolumab, Roche / Genentech.
- TrialA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Shares Axitinib, Pembrolizumab.
- TrialSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With
Shares Axitinib, Renal cell carcinoma.
- TrialA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Shares Tiragolumab, Roche / Genentech.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab.
- TrialKEYNOTE-426
Shares Axitinib, Renal cell carcinoma, Pembrolizumab.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li
Shares Tiragolumab, Roche / Genentech.
- PairingIMDC risk → first-line regimen choice (RCC)
Shares Axitinib, Renal cell carcinoma, Pembrolizumab.